Peer Review

Novartis veteran David Epstein takes leadership role at Rubius

⇨ Novartis vet David Epstein is expanding his role at Rubius, taking the executive chairman’s post at the cell therapy company. In taking the post, the Flagship exec noted:  “I believe Rubius’ pioneering of the next generation of cellular therapy will meaningfully impact patients’ lives.”

⇨ James S. Scibetta has jumped ship at Pacira, taking the CEO’s job at Brisbane, CA-based Maverick Therapeutics. Maverick is working on immuno-oncology, specializing in T cell therapies.

⇨ Not long after retiring from GlaxoSmithKline, Moncef Slaoui started signing up for a variety of biotech boards. There was a seat at the table for SutroVax, mRNA player Moderna as well as the public outfit Intellia. You can now count Intellia out: in an SEC filing, Slaoui had abruptly departed on Monday “due to a conflict of interest.”

⇨ Advancing out of New York’s Accelerator Corporation, Petra Pharma has assembled its executive team. The biotech will be led by Brian O’Callaghan, chief executive officer, David McElligott, chief scientific officer, David Renas, chief financial officer and Paul Sekhri, chairman of the board.

⇨ The gene therapy biotech Orchard Therapeutics has recruited PTC vet Mark Rothera as its new CEO. Rothera had been the chief commercial officer of the Duchenne muscular disease biotech.

Allan Reine is now CFO at Pieris Pharmaceuticals.

 


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Bulletin Healthcare

Immuno Oncology 360